Current trends in small cell lung cancer management —ASCO 2019 update

SummaryDuring the last 30  years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited disease. In extensive disease, platinum/etoposide and topotecan remain the s tandard systemic approaches in the first- and second-line setting, respectively. The only notable improvement was communicated in the IMpower133 trial, by the addition of atezolizumab to the platinum/etoposide chemotherapy backbone. Against this background, the current article aims to review the mos t important abstracts presented at ASCO 2019 along with their potential impact for current clinical practice.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research